APOBEC3C Knockout TE1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the TE1 human esophageal squamous carcinoma cell line. This gene-disruption model targets the APOBEC3C locus, ablating expression of the APOBEC3C cytidine deaminase. The polyclonal pool retains allelic heterogeneity while achieving functional loss of gene activity, providing a robust substrate for studying APOBEC3C-dependent processes in an esophageal cancer context.
The TE1 cell line is a well-established model of human esophageal squamous cell carcinoma (ESCC), originally isolated from a primary tumor. These epithelial cells display hallmark features of ESCC, including genetic instability and dysregulated signaling pathways. TE1 cells are widely employed in oncology research to investigate tumorigenesis, metastasis, and drug response, offering a clinically relevant platform for functional genomics studies.
APOBEC3C is a single-stranded DNA cytidine deaminase that catalyzes C-to-U editing, generating C-to-T transition mutations. Its expression is induced by interferon-??/?? via JAK-STAT signaling, with STAT1 and IRF1 serving as primary transcriptional activators. The enzyme interacts with HIV-1 Vif, the uracil-DNA glycosylase UNG2, and the ApoB mRNA editing complex. Downstream, APOBEC3C-mediated deamination restricts retroviruses and retrotransposons through lethal hypermutation, while its off-target activity on host DNA contributes to cancer-associated mutagenesis. UNG2 counteracts this by initiating base excision repair, modulating the overall mutation load.
In esophageal squamous cell carcinoma, APOBEC3C expression has been implicated as a source of endogenous mutation signatures, potentially driving tumor heterogeneity and therapeutic resistance. Knockout of APOBEC3C in TE1 polyclonal cells provides a means to dissect its contribution to the ESCC mutational landscape. This model enables investigation of how loss of APOBEC3C-mediated deamination affects genomic stability, cell proliferation, and response to chemotherapeutic agents. Moreover, since APOBEC3C participates in innate immune responses, its disruption allows researchers to evaluate crosstalk between antiviral defense pathways and cancer cell-intrinsic signaling networks.
Researchers can employ APOBEC3C knockout TE1 polyclonal cells to delineate mutation signatures via whole-genome or targeted sequencing, directly comparing mutational profiles with those of wild-type TE1 cells. Western blotting and RT-qPCR confirm gene disruption, while deaminase activity assays quantify residual enzymatic function. Drug sensitivity studies can assess APOBEC3C??s influence on chemotherapeutic response. Additionally, the model supports investigation of innate antiviral pathways and cancer evolution, as APOBEC3C sits at the nexus of viral restriction and genomic mutagenesis. For further technical information, please contact Ascent Research.
